Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence

Tocotrienol (T3) is a subfamily of vitamin E known for its wide array of medicinal properties. This review aimed to summarize the health benefits of T3, particularly in prevention or treatment of non-communicable diseases (NCDs), including cardiovascular, musculoskeletal, metabolic, gastric, and ski...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nutrients 2020-01, Vol.12 (1), p.259
Hauptverfasser: Wong, Sok Kuan, Kamisah, Yusof, Mohamed, Norazlina, Muhammad, Norliza, Masbah, Norliana, Fahami, Nur Azlina Mohd, Mohamed, Isa Naina, Shuid, Ahmad Nazun, Saad, Qodriyah Mohd, Abdullah, Azman, Mohamad, Nur-Vaizura, Ibrahim, Nurul' Izzah, Pang, Kok-Lun, Chow, Yoke Yue, Thong, Benjamin Ka Seng, Subramaniam, Shaanthana, Chan, Chin Yi, Ima-Nirwana, Soelaiman, Chin, And Kok-Yong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tocotrienol (T3) is a subfamily of vitamin E known for its wide array of medicinal properties. This review aimed to summarize the health benefits of T3, particularly in prevention or treatment of non-communicable diseases (NCDs), including cardiovascular, musculoskeletal, metabolic, gastric, and skin disorders, as well as cancers. Studies showed that T3 could prevent various NCDs, by suppressing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the mevalonate pathway, inflammatory response, oxidative stress, and alternating hormones. The efficacy of T3 in preventing/treating these NCDs is similar or greater compared to tocopherol (TF). TF may lower the efficacy of T3 because the efficacy of the combination of TF and T3 was lower than T3 alone in some studies. Data investigating the effects of T3 on osteoporosis, arthritis, and peptic ulcers in human are limited. The positive outcomes of T3 treatment obtained from the preclinical studies warrant further validation from clinical trials.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu12010259